Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Weiming Fan

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Bioorganic & Medicinal Chemistry Letters|November 7, 2015
Novel orally active inhibitors of β-1,3-glucan synthesis derived from enfumafunginJames M Apgar, Robert R Wilkening, Mark L Greenlee, et al.
Bioorganic & Medicinal Chemistry Letters|November 7, 2020
Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitorJames M Apgar, Robert R Wilkening, Dann L Parker, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2020
MK-5204: An orally active β-1,3-glucan synthesis inhibitorJames M Apgar, Robert R Wilkening, Dann L Parker, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Bioorganic & Medicinal Chemistry Letters|November 7, 2015
Novel orally active inhibitors of β-1,3-glucan synthesis derived from enfumafunginJames M Apgar, Robert R Wilkening, Mark L Greenlee, et al.
Bioorganic & Medicinal Chemistry Letters|November 7, 2020
Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitorJames M Apgar, Robert R Wilkening, Dann L Parker, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2020
MK-5204: An orally active β-1,3-glucan synthesis inhibitorJames M Apgar, Robert R Wilkening, Dann L Parker, et al.
Pageof 3